Podcasts about BMS

In this episode of The Atrium, host Alice Copperwheat speaks with Jessica Donington, Professor of Surgery and Chief of the Section of Thoracic Surgery at the University of Chicago, Illinois, USA, about neoadjuvant chemoimmunotherapy. Chapters 00:00 Intro 01:20 Why CT Surgery? 04:16 History 06:55 Patient Perception 08:42 Function, Why? 12:40 Patient Selection, Who? 18:20 Resectability 25:31 Types of Neoadj Therapy, What? 30:06 Evidence 33:01 Surgeon Responsibility 39:02 Robotics 39:54 Post Op Considerations 41:29 Key Points 43:12 Surgical Training Advice The discussion emphasizes the importance of being upfront and honest during patient conversations. It explores the benefits of neoadjuvant chemoimmunotherapy, how patients are selected for these treatments, and the various clinical trials on this topic. The conversation also addresses the chemo-radiation route and the clinical assessment of resectability. They also examine how to determine if a tumor is resectable and what factors are assessed during this process. It also highlights the need to consider whether a planned lobectomy might necessitate a pneumonectomy following neoadjuvant chemoimmunotherapy. The conversation also covers chemotherapy, immunotherapy, and targeted therapy, outlining what trainees should remember about each. Finally, they address the complexities of neoadjuvant chemoimmunotherapy, key takeaways for trainees, and the importance of working closely with the entire multidisciplinary team throughout the process. The Atrium is a monthly podcast presenting clinical and career-focused topics for residents and early career professionals across all cardiothoracic surgery subspecialties. Keep an eye out for next month's episode.     Disclosure Dr. Donington serves as an advisor, consultant, and speaker for AstraZeneca, BMS, Genentech/Roche, and Merck. Additionally, she acts as a consultant for Biodesix and an advisor for Lilly.     Disclaimer The information and views presented on CTSNet.org represent the views of the authors and contributors of the material and not of CTSNet. Please review our full disclaimer page here.

Butler Manufacturing Services has been making sewerage treatment systems in Co Longford for 40 years. It accounts some of the biggest house builders among its customers as well as international water authorities. But these systems do not use corrosive or damaging chemicals to clean water for estates and towns of up to 5,000 people. The founder and boss of BMS, Seamus Butler has been chosen as the ‘Green Businessperson of the Month' for September courtesy of Repak.

Synopsis: The drug discovery industry faces a persistent challenge: 9 out of 10 drugs entering the clinic fail, underscoring the need for a better path from biological insight to transformative medicine. Host Rahul Chaturvedi speaks with Robert Plenge, Executive Vice President and Chief Research Officer at Bristol Myers Squibb, about how causal human biology, genetics, novel targets, and emerging technologies are reshaping drug discovery. Robert traces his unconventional journey from aspiring orthopedic surgeon to physician-scientist, human geneticist, and R&D leader, sharing how treating patients with autoimmune disease exposed the gap between controlling symptoms and creating medicines capable of fundamentally changing the course of disease. He explains why understanding causal human biology is critical to improving clinical success rates—and why an industry-wide concentration on the same validated targets risks limiting true innovation. The conversation explores BMS's approach to target diversity and first-in-class innovation, the promise of immune reset and functional cures in autoimmune disease, and how targeted protein degradation is creating new possibilities for patients. Robert also offers a measured view of AI in R&D—from designing higher-quality molecules faster to modeling early clinical data—while emphasizing that technology still depends on understanding the underlying biology. Robert and Rahul also examine the rise of “blended innovation,” where academia, biotech, pharma, and technology partners increasingly work through interconnected ecosystems rather than a traditional linear handoff. Beyond science, Robert shares candid lessons on mentorship, failure, uncertainty, and navigating the “jagged line” of a career—ending with a memorable principle: hold your why tightly and your how loosely. Tune in for a wide-ranging conversation on what it will take to move beyond incremental drug development and build the next generation of medicines. Biography: Robert Plenge, MD, PhD is Executive Vice President and Chief Research Officer at Bristol Myers Squibb, where he leads scientific activities across nine research sites around the world, all focused on transforming patients' lives through science. Prior to his current role, Robert served as head of Discovery & Translational Sciences at BMS, a role that spanned all therapeutic areas at the company. Robert joined BMS as part of the Celgene acquisition in November 2019. At Celgene, he served as vice president, Immunology & Inflammation portfolio, Research & Early Development. Prior to joining Celgene, Robert was vice president and Head of Translational Medicine at Merck. Robert received his MD and PhD from Case Western Reserve University and holds a BS from the University of California, San Diego. He completed his internal medicine residency as a molecular medicine fellow at the University of California, San Francisco. He served as rheumatology fellow at Brigham & Women's Hospital and postdoctoral research fellow at the Broad Institute of MIT and Harvard. He was an assistant professor of medicine at Harvard Medical School and an associate member of the Broad Institute while practicing clinical rheumatology and running a research laboratory at Brigham & Women's Hospital. Robert is an author of more than 125 manuscripts published in peer-reviewed journals, and frequently posts updates to his personal blog, Plenge Gen, commenting on critical discovery moments with a focus on the resulting patient impact. He is a recipient of several academic and corporate awards and currently serves on the Board of Directors for BioMarin, Alltrna and the PhRMA Foundation.

Kopfhörer-Verbot, Müll-Sünden und No-Gos im Startblock: Wie verhält man sich bei einem Marathon oder HM wirklich richtig? In dieser Folge haben wir Race-Director Steven Richter von der Laufgesellschaft (u. A. hella hamburg halbmarathon) zu Gast. Er gibt spannende Einblicke hinter die Kulissen von Laufveranstaltungen, erklärt den offiziellen „Race-Knigge“ und verrät, welche Fauxpas zur sofortigen Disqualifikation führen. Außerdem beantworten wir dringende Fragen aus der Community: Warum steigen die Startgebühren, was passiert, wenn ein Rennen verschoben werden muss - und warum gibt es immer zu wenig Dixis?! Jetzt reinhören und perfekt vorbereitet am nächsten Renntag an den Start gehen!(00:01:40) - Intro Ende(00:09:35) - Regel-Missbrauch und Verhaltensfehler(00:21:28) - Fehler im Startblock(00:33:45) - Übernahme von Startnummern: Why not?(00:53:15) - Diese Regeln kennt niemand(00:59:35) - Vom Wildpinkeln bis zur Disqualifikation(01:13:00) - Stau & Hamstern an den Verpflegungsstationen(01:19:30) - Wie entstehen die hohen Anmeldegebühren?(01:32:35) - Die Dixi-Problematik(01:38:50) - Warum wurde der Hella Halbmarathon Hamburg verschoben?Hier findest du die Laufgesellschaft auf Instagram: https://www.instagram.com/dielaufgesellschaft/?hl=deHier findest du Veranstaltungen und mehr von der BMS: https://www.dielaufgesellschaft.de/Foto: Steven RichterMusik: The Artisian Beat - Man of the CenturyHier findest du alle aktuellen Rabatt-Aktionen von unseren Werbepartner:innen! Hosted on Acast. See acast.com/privacy for more information.

I veckans avsnitt av aktiepodden pratar vi ingenting om valet! Desto mer tid lägger vi på att kåsera kring de utmaningar som möter världens största läkemedelsbolag. Många lyfte på ögonbrynen när Astrazenecas fusionsdiskussioner med BMS blev kända. En fusion som vid en första anblick framstod som en dålig affär. Men Lars gör ett försök att förklara logiken bakom en fusion. Oliver kontrar med lite kul fakta kring AI innan diskussionen går in på vårt fokus: Enskilda aktier.I veckan gästades Aktiespararnas event av bland annat Epiroc, Ambea och FM Mattson. Oliver gillade vad han hörde och lyfter fram de faktorer som talar för bolagen samtidigt som Lars försöker skjuta ned hans optimism. Det gick sådär.Lars stod denna gång för veckans case som är BHG Group. Efter medvind 2025 och motvind 2026 undrar många vartåt vindarna blåser 2027. I Aktiepodden får du svaret!

BMS EPISODE 64 (BIG TUNES) Episode 64 features hit tracks played on BMS over the years. Showcasing some of the very best from the 80s and 70s, highlighted and performed by artists such as Sade, Atlantic Starr, Surface, New Edition, Luther Vandross, and many more! DJ Rhythm Dee hosts a recurring segment known as Black Magic Sounds. The show features the smooth grooves of Jazz, Nu Soul, Neo Soul, Funk, R&B, Disco, Soulful House, Slow Jams, and anything that moves you. It's all about feeling the music and hearing forgotten tracks or some entirely new to you.  Remember when music was Music!   PLAYLIST   HANG ON TO YOUR LOVE/SADE  WHEN LOVE CALLS/ATLANTIC STARR  LADY LOVE ME/GEORGE BENSON  THE VERY BEST IN YOU/CHANGE  MY FORBIDDEN LOVER/CHIC  THINKING OF YOU/SISTER SLEDGE  HAPPY/SURFACE  NO ONES GONNA LOVE YOU/S.O.S. BAND  SPECIAL F/X/THE WHISPERS  YOU'RE NOT MY KIND OF GIRL/NEW EDITION  NEVER TOO MUCH/LUTHER VANDROSS  WHATCHA GONNA DO FOR ME/CHAKA KHAN  FLOWERS//THE EMOTIONS  STRAWBERRY LETTER 23/BROTHER'S JOHNSON  LOVE MAKIN' MUSIC/BARRY WHITE  MAN IN THE MIRROR/MICHAEL JACKSON  INHERIT THE WIND/BOBBY WOMACK & WILTON FELDER 

Jacob Townsend is joined by Bristol Motor Speedway general manager, Jerry Caldwell, about the week ahead and festivities at BMS.See omnystudio.com/listener for privacy information.

Hour 4 of September 14, 2026 Jacob Townsend talks with Deb Williams, of Autoweek.com, about Kyle Larson's win at Gateway, good day for Hendrick, look ahead to Bristol, and more. Then, Jacob is joined by Bristol Motor Speedway general manager, Jerry Caldwell, about the week ahead and festivities at BMS. Also, Jacob gives his final thoughts on ETSU's loss at North Carolina. See omnystudio.com/listener for privacy information.

Chef Clayton Parrett has spent more than two decades in kitchens, but he still considers himself a student. Growing up in rural South Louisiana, Clayton's earliest education came from the land. Hunting, fishing, livestock, agriculture and eventually working around a slaughterhouse taught him where food came from long before he understood that cooking would become his life. That path eventually took him offshore, cooking on drilling operations in the Gulf for weeks at a time. The isolation and relentless routine taught him patience, discipline and responsibility, lessons that would follow him through restaurants, universities, convention centers and hotels before ultimately bringing him to the historic Fenway Hotel in Dunedin, Florida. But Clayton says one of the biggest turning points in his career came when he learned something entirely different: How to fail. Accepting failure gave him permission to experiment, take chances and become more curious about food. It also helped shape a philosophy he still carries today. Clayton doesn't particularly believe in mastery. There are too many cultures, ingredients, techniques and traditions he hasn't experienced yet. "I prefer to say I'm a student for life." That curiosity is now helping drive the culinary direction at Fenway, where Clayton and his team are exploring global beef, ingredient provenance and the kind of luxury dining experience capable of competing on a much larger stage. One of their long-term ambitions is earning consideration among the world's leading steakhouses. And Clayton brought that same curiosity into the Walk-In Talk studio. Using wild boar tenderloin from studio partner Shogun Farms, Clayton created a dish rooted deeply in memories of Louisiana, incorporating field peas, persimmon, satsuma, sumac and produce from Cahaba Club. It's a plate built around the landscape and flavors that helped shape him as a chef. He followed it with an entirely different exploration: an antelope croquette with smoked Gouda and three vibrant sauces, combining classical French technique with an ingredient many diners rarely encounter. And then came the beef. Japanese A5 Wagyu rated BMS 12, representing the level of sourcing, education and product knowledge Clayton and his team are working to bring to Fenway. What's Hot Tampa Bay Leah Wilson of Creative Loafing Tampa Bay also returns to the studio for her recurring What's Hot Tampa Bay segment, and this time the conversation is all about Best of the Bay. Leah breaks down how the long-running Tampa Bay competition works, from public nominations and voting to the annual Best of the Bay celebration, and why the recognition means so much to the restaurants, chefs, businesses and personalities selected by the community. There's an added connection this year: Chef Clayton Parrett and Fenway are participating in the Best of the Bay celebration, putting Clayton directly into one of the biggest hospitality and culture events on Creative Loafing Tampa Bay's calendar. It makes for an episode that moves naturally between where a chef comes from, what keeps him learning, the food he is building today and the Tampa Bay community he is now helping shape. Chef Clayton Parrett Fenway Hotel | Dunedin, Florida Featuring Leah Wilson Creative Loafing Tampa Bay | What's Hot Tampa Bay Featuring ingredients from Walk-In Talk Media studio partners Shogun Farms and Cahaba Club. A Walk-In Talk Media production. From the industry. For the industry.     Key Takeaways His culinary education began with the land. Growing up in South Louisiana gave Clayton an early understanding of animals, agriculture, seasonality and the relationship between food and community. Work ethic became survival early. He left home young, lived with friends, finished school and worked long hours because quitting was never really part of the plan. Offshore cooking changed him. Spending weeks at a time on Gulf drilling operations taught him patience, routine, responsibility and how to function when there is nowhere else to go. Learning to fail changed his relationship with food. Clayton says his real passion developed once he understood that failure was acceptable as long as he kept trying. He does not believe the learning ever ends. Rather than chasing the idea of mastery, Clayton sees himself as a lifelong student of ingredients, cultures, techniques and people. Food is education. To Clayton, an ingredient is never just something to cook. It is an opportunity to understand geography, biology, agriculture, culture and technique. Community remains central. Whether talking about Louisiana, hurricanes, family or his kitchen team, Clayton repeatedly comes back to the idea that people survive and grow together. Leadership means giving knowledge away. He wants the cooks who work with him to leave knowing as much as he can possibly teach them. The Fenway's beef program is becoming increasingly ambitious. Clayton is studying breeds, origins, grading systems and global sourcing while building a team capable of understanding luxury beef at a deeper level. Recognition is a goal, but not the purpose. The dream of landing among the world's top steakhouses matters because of what it would say about the work of his team, not because Clayton is chasing a title for himself. The Companies Helping Shape Hospitality Metro Foodservice Solutions - Commercial-grade storage, transport, and workflow systems that help professional kitchens operate efficiently. RAK Porcelain USA - Professional tableware built for performance, durability, and presentation at the highest level. TriMark USA - North America's largest foodservice design, equipment, and supplies provider, helping operators build smarter, more efficient kitchens. Testo North America - Precision measurement and food safety solutions designed for professional hospitality operations. Crab Island Seafood - Florida-based manufacturer of premium seafood dips and spreads inspired by coastal flavors. Citrus America - Commercial juicing solutions delivering consistency, speed, and quality to foodservice operators. Cahaba Club – Growing exceptional herbs, edible flowers, and specialty produce that bring fresh flavor and vibrant presentation to our studio kitchen. Shogun Farms - produces premium Florida wild boar through ethical sourcing, humane raising, and a natural feeding program that delivers exceptional flavor from farm to table. Walk-In Talk Media proudly supports organizations making a measurable impact on hospitality professionals and communities across North America and beyond. Operation BBQ Relief - Disaster response through hot meals served by culinary volunteers across the country. Sustainable Supperclub - Community driven dining experiences focused on sustainability, food access, and social impact. The Burnt Chef Project North America – Supporting mental health awareness and wellbeing throughout the hospitality industry.   Industry Events & Media Partnerships Florida Restaurant Show - Official Media Partner delivering on-site coverage of operators, suppliers, chefs, and hospitality innovation throughout the Southeast.  New York Restaurant Show - Official Media Partner highlighting the people, products, and stories shaping hospitality across the Northeast.  California Restaurant Show - Official Media Partner covering West Coast hospitality innovation, culinary trends, and foodservice leadership.  Pizza Tomorrow Summit - Official Media Partner covering the latest innovations, leadership, and growth in the pizza industry.  U.S. Culinary Open -Official Media Partner documenting one of America's premier live culinary competitions and the chefs competing at the highest level.  Creative Loafing Tampa Bay - Regional media partner sharing stories from the people, restaurants, and events shaping Tampa Bay's hospitality community. About Walk-In Talk Media Walk-In Talk Media is an industry-recognized B2B food and hospitality media company focused on chef-driven storytelling and real conversations inside the business of food.  Through cinematic video, photography, podcasting, documentaries, and live event coverage, Walk-In Talk Media highlights the chefs, operators, brands, and organizations shaping the future of hospitality.  From Michelin-starred chefs and independent restaurants to manufacturers, distributors, and industry associations, Walk-In Talk Media exists to tell the stories moving hospitality forward.

Clinical trials often collect far more blood than an assay actually needs. Dr. Joleen White asks a more disciplined question: What information is required to make a sound decision, and how little sample can be collected without compromising that decision?In this episode of BioTalk Unzipped, recorded at the 2026 AAPS National Biotechnology Conference in San Diego, Dr. Chad Briscoe sits down with Joleen to explore patient-centric sampling, dried blood microsampling, global bioanalytical capacity, and the values behind better drug development.Joleen traces her path from a childhood friendship with someone living with cystic fibrosis to a career spanning BioMarin, BMS, Biogen, EMD Serono, the Gates Medical Research Institute, and BioData Solutions. She explains why bioanalysis became her way to help patients, why she eventually moved beyond the bench, and how global health work changed the way she thinks about laboratory infrastructure and clinical-trial design.The conversation then turns practical. Joleen defines patient-centric sampling, describes the Mitra dried blood collection device, and discusses a first-in-human RSV monoclonal antibody study in which paired dried-blood and serum samples led to aligned PK conclusions. She and Chad examine regulatory acceptance, remote collection, pediatric sampling, local laboratory capacity in African countries, scientific inclusion, career choices, AI, mass-spectrometry sensitivity, and whether long-standing sample-volume and stability expectations still serve patients.SponsorsTruTechnologies provides live clinical trial execution and oversight through point-of-care data capture. Learn more: https://trutechnologies.ai/Leucentra provides specialized IT consulting and services for life sciences and healthcare. Learn more: https://leucentra.com/In this episode, you will hear• How a personal connection to cystic fibrosis shaped Joleen's patient-first career• Why bioanalysis connects analytical rigor to decisions about drug safety, exposure, and patient benefit• What patient-centric sampling means beyond simply collecting less blood• How dried blood microsampling can support PK, immunogenicity, and viral-neutralization assessments• What Joleen's team learned by comparing dried blood with serum in a first-in-human study• Why smaller samples and remote collection can reduce burdens on patients, caregivers, sites, and enrollment• Why sustainable global health research depends on locally led scientific and laboratory capacity• How legacy automation can slow innovation and create opportunities for newer laboratory networks• Why inclusion and access expand both the scientific workforce and the quality of science• How personal values can guide career decisions more effectively than a rigid five-year plan• Why advances in mass spectrometry should prompt a fresh look at sample volumes and stability expectationsGuest and hostDr. Joleen White is a Senior Bioanalytical Consultant at BioData Solutions with more than 20 years of experience across regulated bioanalysis, ligand-binding assays, immunogenicity, cell-based assays, neutralizing-antibody assays, and data science.Connect with Joleen: https://www.linkedin.com/in/joleenwhite/BioData Solutions: https://www.bdatasolutions.com/Dr. Chad Briscoe is the co-host of BioTalk Unzipped and conducts this onsite conversation from AAPS NBC.Connect with Chad: https://www.linkedin.com/in/chadbriscoe/Resources mentionedOpen-access RSM01 dried blood microsampling study:https://pubmed.ncbi.nlm.nih.gov/39696004/Patient Centric Sampling Interest Group:https://www.pcsig.org/Follow BioTalk UnzippedWebsite and all episodes: https://www.biotalkunzipped.com/YouTube: https://www.youtube.com/@BioTalkUnzippedBioTalk Unzipped unzips, unlocks, and uncovers the real stories behind medical progress.

On Twitter and YouTube, Dinesh D'Souza has been criticizing Calvinism (i.e. Reformed theology) for weeks, leveling both scriptural but also philosophical and moral objections. Bob adopts his version of Molinism to argue that God's sovereignty can be reconciled with man's free will (and hence moral culpability).Mentioned in the Episode and Other Links of Interest:Dinesh D'Souza's critique of Calvinism.RC Sproul's YouTube series introducing systematic Reformed theology.William Lane Craig quick intro to Molinism.The BMS ep. 158, A Geometric Analogy to Reconcile Paul and James.Installments one and three in the BMS series on an Interdisciplinary Commentary on the Gospels, laying out Bob's view of free will vs. determinism, and how to reconcile Arminianism with Calvinism.Help support the Bob Murphy Show.

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into a series of significant advancements and regulatory milestones that underscore the industry's commitment to addressing complex health challenges with innovative therapeutics and strategic investments. Eli Lilly has achieved a major breakthrough with the FDA approval of Mounjaro (tirzepatide), a dual GLP-1/GIP agonist designed to reduce cardiovascular risks in individuals with type 2 diabetes. This marks a pivotal step forward in diabetes management, as it not only improves glycemic control but also offers cardiovascular protection. The approval of tirzepatide highlights the therapeutic potential of dual agonists in metabolic disorders, setting a new standard for diabetes care. This development places Eli Lilly at the forefront of incretin-based therapies, a crucial advancement given the high cardiovascular risk associated with diabetes. Priovant Therapeutics has secured its first FDA approval for Lisraya (brepocitinib), a novel TYK2/JAK1 inhibitor tablet aimed at treating dermatomyositis, an autoimmune condition characterized by muscle inflammation and skin rash. As a first-in-class therapeutic option, brepocitinib underscores the growing focus on targeted therapies that modulate specific pathways involved in autoimmune diseases. Priovant's success, following its acquisition from Pfizer, signals its emergence as a significant player in rare disease treatment. Bristol Myers Squibb is making waves with a $173 million investment to construct a second radiopharmaceutical manufacturing facility in Indiana. This strategic move aligns with the increasing demand for precision oncology treatments that utilize radiolabeled compounds for targeted cancer therapy. BMS's investment demonstrates a strong commitment to advancing personalized medicine and meeting future demands in this rapidly evolving field. Gilead Sciences has received FDA approval for Bixlenvo (bictegravir/lenacapavir), an integrase/capsid inhibitor combination pill for virologically suppressed HIV patients. This small molecule therapy offers a potent antiviral strategy by combining two mechanisms of action—integrase inhibition and capsid disruption—enhancing long-term viral suppression for HIV patients. This represents an evolution in HIV treatment, promising improved adherence and patient outcomes. In China, Hutchmed's Atled (fanregratinib) has been approved by the NMPA for treating FGFR2-fusion intrahepatic cholangiocarcinoma after successful Phase 2 trials. Fanregratinib exemplifies precision medicine's approach by targeting specific genetic alterations driving cancer progression, offering new hope for patients with this challenging condition. Cytokinetics has reported promising Phase 3 results for Myqorzo (aficamten) in non-obstructive hypertrophic cardiomyopathy. Aficamten acts as a cardiac myosin inhibitor, representing a novel therapeutic avenue that directly targets the underlying pathophysiology of this rare heart disorder. The positive outcomes from these trials support its bid for FDA approval and could expand treatment options significantly. In respiratory disease research, Generate Bio's GB-0895 has shown encouraging Phase 1 biomarker reductions in chronic obstructive pulmonary disease (COPD). This monoclonal antibody approach targets TSLP and marks progress in developing new therapies for respiratory diseases with high unmet needs. Teva Pharmaceuticals has positioned itself as the stalking horse bidder for BioXcel Therapeutics' neuroscience portfolio amid bankruptcy proceedings. Teva's bid highlights ongoing consolidation trends within the pharmaceutical industry as companies seek to bolster their portfolios through strategic acquisitions. Roche's Genentech announced a substantial deal with DualityBio worth over $1 billion for antibody-drug conjugates (ADCs), focusing on developing treatments for cancers resistant to existing ADC therapies. This partnership showcases Roche's commitment to addressing complex oncology challenges through innovative modalities. Furthermore, AusperBio has secured $120 million in series C funding to advance its oligonucleotide therapy for chronic hepatitis B through Phase 3 trials. Such funding milestones demonstrate robust investor confidence and highlight promising advancements in oligonucleotide therapeutics for chronic infections like hepatitis B. These scientific advancements highlight the dynamic landscape of the biotech and pharmaceutical industries, characterized by innovation-driven solutions across various therapeutic areas. The emphasis on targeted therapies, precision medicine, and strategic investments underscores the sector's dedication to enhancing patient care through cutting-edge science and technology. As these developments unfold, they hold significant potential to impact treatment paradigms, offering hope for improved outcomes across various diseases with high unmet needs. The industry's focus on cutting-edge research and strategic collaborations continues to drive innovations that could redefine therapeutic landscapes globally. Thank you for tuning into Pharma Daily—your source for reliable updates on the evolving world of pharmaceuticals and biotechnology. Join us next time as we continue to explore groundbreaking advancements shaping patient care worldwide.Support the show

C'est mieux de boycotter de manière imparfaite Sony mais Keusmo va acheter GTA 6 à tout jamais quand même.Au menu dans le cockpit : Joël BMS viens debrief avec nous le trailer monstrueux de GTA, nos théories, nos attentes.... et on a parlé de nos ex et de mariage (??). Dégustez c'est pas tous les jours.Lien de notre offre avec Trade Republic : https://chck.me/m63k 30€ d'actions offertes chez des marques qu'on kiffe genre adidas, Uniqlo etc.. dès la création d'un nouveau compte via le lien (faudra juste créditer 100 euros sur ton compte et faire 2 investissements de 1€ minimum)Collaboration commercialeInvestir comporte des risques. Offre à 3% par an sur les liquidités jusqu'à 50 000 € pour les nouveaux clients. Percevez des intérêts de banques partenaires, des dividendes de fonds de liquidité (soumis au risque de marché) et un complément de notre part. Les intérêts et gains financiers sont soumis aux prélèvements fiscaux et sociaux. Offre à la discrétion de la banque, sous réserve des conditions générales. Les valeurs sont données à titre indicatif. Conditions générales applicables au tirage au sort et au bonus de bienvenue.En live tous les jours du Lundi au Vendredi à 8h sur Twitch et Youtube ! Hébergé par Acast. Visitez acast.com/privacy pour plus d'informations.

BMS/2300 JACKSON STREET  I was 9 years old when the Jackson 5 burst onto the music scene, expressing their talent, youthfulness, and color. I cannot describe the excitement my siblings and I had when we heard their songs on the radio or saw them on television. This episode features the contributions of all 9 children to the music industry and the tapestry they formed as the backdrop of our lives.  Remember when music was Music!   Playlist   THE LOVE YOU SAVE THE JACKSON 5  LOOKIN' THROUGH THE WINDOW THE JACKSON 5  WE'RE ALMOST THERE MICHAEL JACKSON  ALL I DO IS THINK OF YOU THE JACKSON 5  DANCING MACHINE THE JACKSON 5  LET'S GET SERIOUS JERMAINE JACKSON  CAN YOU FEEL IT THE JACKSONS  I LIKE YOUR STYLE JERMAINE JACKSON  THE LADY IN MY LIFE MICHAEL JACKSON  YOUNG LOVE JANET JACKSON  TELL ME I'M NOT DREAMIN' JERMAINE JACKSON  CONTROL JANET JACKSON  CENTIPEDE REBBIE JACKSON  WHEN I THINK OF YOU JANET JACKSON  REACTION REBBIE JACKSON  LUV U HONEY RANDY & THE GYPSIES  BREAK OF DAWN MICHAEL JACKSON  2300 JACKSON ST THE JACKSONS   

We Like Shooting We Like Shooting - Ep 676 August 17, 2026 Presented by This episode of We Like Shooting is brought to you by: Foxtrot Mike (Code: WLSISLIFE) C&G Holsters (Code: WLSISLIFE) Gideon Optics (Code: WLSISLIFE) Midwest Industries (Code: WLSISLIFE) Blue Alpha Night Fision (Code: WLSISLIFE) Otis Technology (Code: WELIKESHOOTING15) Giveaways!! GAW   Text Dear WLS or Reviews +1 743 500 2171 Public   Show Titles   Gear Chat Note Montana Knife Company stoned goat ultrahttps://www.montanaknifecompany.com/products/stoned-goat-ultra EAA Corp. Girsan Witness2311 CMX XXX Discover the Witness2311 CMX XXX, a compact double stack 1911 with 16+1 capacity, a slim grip, firing pin block safety, and two-tone finish. The Girsan Witness2311 CMX XXX is a compact single-action 9mm pistol from EAA Corp. with 16+1 capacity using Check-Mate magazines. It features an RMSc-footprint optic-ready slide, 3.4-inch coned barrel, two-tone Cerakote finish, low-profile 3-dot sights, ambidextrous thumb safety, 4-slot Picatinny rail, and EAA limited lifetime warranty. Availability: Available for purchase via Add to Cart on eaacorp.com (no explicit stock, release date or additional retailers stated) Cost: $899 Special: Streamlined compact grip with aggressive texturing, low-profile magwell, and automatic firing pin block safety replacing traditional grip safety for 16+1 capacity without added bulk Odysee (Nick) SecondWatch FTN.6 Suppressor Pack Update: We received overwhelming feedback that people did not like the text. The intention was to save on what needed to be engraved. Since it is so unpopular, all text has been removed from the model… The FTN.6 Suppressor Pack is a downloadable set of 3D-printable files for DIY suppressors released by SecondWatch on August 15, 2026, via Odysee. It includes updated designs for rimfire, 5.56, and 300 BLK models that are described as the quietest FTN variants to date, matching or surpassing many commercial suppressors in head-to-head testing. The pack continues the FTN (Fuck The NFA) series focused on accessible, low-cost polymer printed silencers. Availability: Released August 15, 2026 on Odysee (@SecondWatch); downloadable files Special: FTN.6 Air is a very lightweight (~10.6 oz) and slim rifle suppressor using thread adapters; modular flash hider and compensator add-ons; FTN.6 Rimfire offers similar sound reduction to FTN.5 but in a smaller package Defiance Machine (Nick) Defiance Machine Deviant Comp Rifle Action Deviant COMP – The new standard for PRS competitors. The Deviant COMP refines our popular Deviant model into a purpose-built precision rifle action designed specifically for PRS competitors who demand speed, consistency, and reliability under pressure. Built with the features competitive shooters actually want, the Deviant COMP features an oversized bolt for fast cycling, an AW magazine cut compatible with both AW and AICS magazines, and guaranteed headspace for repeatable accuracy and hassle-free builds. This makes the Deviant COMP a competition-ready package that is ideal for PRS. Finished with nitride included at no additional cost, the Deviant COMP delivers premium performance at an exceptional value. Specifications Integral scope mount/rail. Integral recoil lug. Defiance swept legacy bolt design. Oversized competition bolt knob. Smooth chrome-moly bolt action with anti-bind design. Recessed bolt lugs, Mini-16 extractor, and plunger ejector. AW magazine cut. Trigger pins included. Nitride finish included. Why choose the Deviant COMP? PRS competition-ready feature set. Integral rail and recoil lug means more rigidity and reliability when it matters most. Receiver is made from once piece of pre-hardened aircraft-certified 416 stainless steel, allowing for tight manufacturing tolerances and increased performance. One-piece legacy bolt, machined to exacting tolerances required to cycle as smooth as possible. Swept bolt handle design to allow plenty of clearance with your rifle scope. Precision extraction system that significantly increases initial extraction and improves smooth bolt cycling. Need an extra bolt? Extra bolts are available when purchasing your action over the phone with our team for $495 each (includes extractor, ejector, and fire control assembly). The Deviant Comp is a purpose-built short-action bolt-action receiver from Defiance Machine, refined from the standard Deviant for PRS competitors. It is machined from a single piece of pre-hardened 416 stainless steel with an integral scope rail and recoil lug for rigidity and guaranteed headspace. It features an oversized competition bolt knob, swept bolt handle, anti-bind design, AW/AICS magazine compatibility, nitride finish, and a smooth chrome-moly bolt with recessed lugs, Mini-16 extractor, and plunger ejector. Availability: Available through retailers including Red Hawk Rifles (add-to-cart with options) and Altus Shooting (currently out of stock for specific variants like RH/308) Cost: $1,495.00 Special: PRS-optimized with oversized bolt for fast cycling, AW magazine cut compatible with AW and AICS, integral rail/lug for rigidity, and included nitride finish at no extra cost 270 Videos Removed from YouTube for FRN and WLS in Recent Days 270 videos removed from youtube for FRN and WLS in the last several days. Supplementary Research: Firearms Radio Network (FRN) produces multiple gun-related podcasts including the long-running We Like Shooting (WLS) show, which features discussions on firearms, gear, training, and current events. The claim states that 270 videos associated with these channels were removed from YouTube over several days in 2026. YouTube's enforcement actions in 2026 have included widespread removals tied to updated policies on AI-generated content, community guidelines, and monetization standards, with millions of videos and channels affected platform-wide. Gun Fights Play the best Price Is Right-style GunBroker game on the internet. Gun Fights Live DisplayFollow the game, prices, and reveals as they happen.Open the live display BangRank A live cast ranking segment for anything and everything in the gun world, powered by questionable certainty, strong opinions, and audience voting. BangRank Live VotingScan or open the link to rank along with the show.https://welikeshooting.com/rank   WLS is Lifestyle GunCAD Index 2011 OPTICS MAXXING by Foaps Files Designed specifically for the Nightalliance 2011 Maxxing frames. There are two styles to choose from and six different optic mounting patterns. Each … This is a 3D model release on GunCAD Index containing STEP and STL files for optic mounts designed specifically for Nightalliance 2011 Maxxing frames. It offers two styles, six optic mounting patterns (including ACRO, Docter-Noblex, Pic Rail, RMR, RMSc, T1-T2), Gas Pedal and Non-Gas Pedal variants, plus length options for Full, Commander, and Short frames. The page serves as an indexed preview only; actual files must be acquired from the original source. Why it Matters: Enables precise red-dot integration on custom 2011 pistols in the growing 3D2A community, allowing shooters to upgrade iron-sight platforms with modern optics without factory limitations. The Vibe: Clean, modular CAD aesthetic with purposeful engineering details—gas pedal extensions, multi-pattern plates, and frame-specific lengths that emphasize performance-oriented customization over factory aesthetics. Hot Take: In the 2011 maxxing scene, bolting a quality optic directly to a printed or custom frame is now the baseline, not an afterthought. GunCAD Index Freedomware Sedco SP22:8 SPEDBRO SP22 Printable 22LR Pistol Don't like the standard Jennings J22? Well here's his neglected brother, the Sedco SP22. A knockoff of the already trash J22. NOT FOR DISTRIBUTION O… The SPEDBRO SP22 is a 3D-printable knockoff of the Sedco SP22 / Jennings J22 design by FreedomWare. It is a rimfire 22 Long Rifle handgun classified as a printed firearm using DIY barrel, bolt, and fire control with no firearm parts required. The release includes multiple STL files, reference images, a drill key, and README; total size 2.5 MiB; explicitly not for distribution on DEFCAD; tagged for FOSSCAD and 3D2A. Why it Matters: Provides a fully printable 22LR plinking handgun design that requires no commercial firearm parts, enabling DIY production of a simple rimfire pistol using consumer 3D printing and basic tools. The Vibe: Utilitarian homemade aesthetic with blocky printed polymer grips and frame, exposed metal DIY barrel/bolt, and reference photos showing side-by-side comparison to a Bryco 22; raw FOSSCAD open-source vibe with technical STL and drill-key files. Hot Take: A knockoff of the already trash J22 – the neglected brother Sedco SP22 now lives on as a fully printable FreedomWare project for the 3D2A community. Guncadindex Tritschi 60 Seconds Timer for Shooting Range A self-built horizontal hourglass-style mechanical countdown timer using a stepper motor, GT2 belt, Nema17, Arduino Nano, and 3D-printed parts. It provides a large 160 cm x 90 mm visual window that transitions from white to red over exactly 60 seconds for timing K20-K23 handgun events in DSU disciplines, with startup red LED/beeper sequence, green LED indicator, optional beeper, and planned light-sensor start. Powered by 3S Li-Ion with BMS; designed in TinkerCad and printed on Prusa MK4/Sovol SV08. Why it Matters: Best Use Case: Competition (K20-K23 handgun events in German DSU shooting sports; helps pace 18 shots in 60 seconds without digital distractions or crowd noise) Hot Take: Quick Pro/Con: Pro – Large peripheral-vision mechanical analog display improves focus and timing accuracy; Con – Self-built (requires 3D printing,...

On Sunday, we were blessed to have Roger and Ingrid Hamlett with us, they are BMS missionaries in chad and shared about their work. Luke preached this short message looking at the great commission afterwards

A control valve can look right on paper and still create control problems in the field. For building automation professionals, valve sizing directly affects what you see at the controller. Unstable loops, limited valve travel, poor response, and persistent comfort complaints may appear to be programming or tuning issues when the real problem started with valve selection. In Episode 557 of the Smart Buildings Academy Podcast, Valve Sizing 101, you'll learn how to think about control valves as precision control elements rather than simple devices for passing water. Understanding what happens between valve sizing, pressure drop, authority, and the coil can help you recognize when a hydronic problem needs more than another round of loop tuning. Topics Covered • Why valve sizing matters to BMS technicians and controls professionals • How valve authority affects modulation and control stability • What oversizing can do to valve performance and usable range • Why valve characteristics matter for heating and cooling coils • Where cavitation and flashing enter the valve sizing conversation If you work with hydronic systems, AHUs, terminal units, or control loops, this episode will help you connect what you see in the BMS to what is happening at the valve.

It's ev.news Briefly for Tuesday 04 August 2026, only today's headlines and just the facts in just 4 minutes if you haven't got time for the full show.Patreon supporters fund this show, get the episodes ad free, as soon as they're ready and are part of the ev.news Community. You can be like them by clicking here: https://www.patreon.com/evnewsEVS TAKE THE LEAD IN IRELAND'S NEW-CAR MARKET AS JULY HITS NEW RECORDBattery electric vehicles have become Ireland's top new-car fuel type, with July setting a record of 9,682 BEV registrations, up 97.67% year on year, taking the seven-month total to 29,840 units, a 61.06% rise on 2025. EVs held 26.1% of the market over that period, ahead of petrol-electric hybrids at 24.6%, petrol at 20.4%, PHEVs at 14.5% and diesel at 12.5%, with Nevo's Derek Reilly crediting lower running costs, newer technology and models priced between €20,000 and €30,000 for reaching the tipping point.VOLVO EX50 SET FOR US IN 2027Volvo will bring the EX50 compact electric crossover to US and Canadian showrooms in autumn 2027 at a price in the high $40,000s, replacing the EX40 as its entry-level US EV and filling a gap left when the EX30 and EX30 Cross Country exit after the 2026 model year. Production starts in spring 2027 at Volvo's $1.3 billion, 250,000-unit Kosice plant in Slovakia, using the SPA3 modular platform with an 800-volt system for faster charging, better efficiency and flexible battery and motor combinations.HYUNDAI AND KIA TOP 100,000 EUROPE EVSHyundai and Kia sold a combined 131,032 EVs in Europe in H1 2026, their first half-year above 100,000, putting them on course to beat 2025's full-year 183,912, as European BEV registrations rose 33.7% to over 1.24 million and took roughly 22% of the market. The Kia EV3 led with 27,121 units from around €36,000, while cheaper models filled out the range: the Hyundai Inster sold 16,594 units, the Kia EV2 launched in Germany in March at €26,600, and the EV4 added 14,502 units during its ramp-up.FRENCH BEV SHARE HITS 35% IN JULYBattery-electric cars took 35% of French new-car registrations in July 2026, with the PFA recording 44,378 BEVs from a market of 126,808 units that grew 9% year on year, roughly double the share of two years earlier. The rise coincided with Round 3 of France's social leasing scheme, reopened on July 16, which covers 29% of purchase price up to €6,500, rising to €9,000 for EEA-built vehicles and batteries plus €500 for an EEA motor, caps payments at €200 a month with no deposit, and has drawn offers such as the Citroën ë-C3 from €94 a month and Renault Twingo from €130.NORWAY HITS 97.6% EV SHARE IN JULYNorway registered 9,609 new passenger cars in July, up 0.5% year on year, of which 9,379 were battery-electric, a 97.6% share up from 96.9% in June, while Østfold reached 99.6% with 672 of 675 registrations. Used-market data followed suit, with private ownership transfers of used EVs up 8% in July against falls of 5.7% for diesel and 6.7% for petrol, and year-to-date used EV transfers up 43.2% to 103,892, now ahead of diesel overall.ALSO STARTS TM-B DELIVERIES AFTER DELAYAlso will deliver its first Launch Edition TM-B electric bikes this week through mid-September, ending a delay caused by an industry-wide surge in demand for raw materials and electronic components that left the bike short of key parts and stalled its manufacturing ramp-up. The TM-B uses a pedal-by-wire system in which pedalling spins a generator that communicates with the motor, with no mechanical link to the wheel, alongside a slick interface, over-the-air updates and a modular frame that accepts different seats and cargo racks.NISSAN SHOWS INTERSTAR-E ELECTRIC CAMPERVANNissan and German converter Eifelland will debut the Interstar-e Relax electric campervan at the Caravan Salon in Düsseldorf this month, using a Truma Eezy parking heater powered by vehicle-to-load from the 87 kWh traction battery, removing the need for a campsite hookup, diesel generator or engine idling. The donor van is rated at up to 255 miles (410 km) WLTP unladen, though the conversion's added weight will cut that materially, with 130 kW DC and 22 kW AC charging, a fixed bed, 90-litre fridge, induction hob, sink, wood trim and portable toilet, priced at €89,900 (about $102,000).CHUNG CHECKS IONIQ 3 TURKEY LAUNCHHyundai Motor Group Executive Chair Chung Eui-sun toured the group's Izmit plant near Istanbul on July 30 to check production readiness and quality control ahead of Ioniq 3 mass production in mid-August, also visiting Hyundai Mobis's Battery System Assembly plant and urging staff to make the car one of Europe's safest. The Ioniq 3 is Hyundai's first subcompact BEV built for Europe and the first EV made at Izmit, which has built combustion compacts since 1997, and it will roll out across Europe in H2 2026 as the first Hyundai there with the next-generation Pleos Connect infotainment system.FARIZON CUTS AUSTRALIAN SV VAN PRICESFarizon has cut prices by up to A$8,500 (US$5,570) across its SV electric van range in Australia, extending EV price competition into the light commercial segment, with revised pricing now starting at A$62,990 (US$41,260) before on-road costs for the SWB. The mid-size SV, with roughly 1t to 1.2t of payload, previously came in SWB low roof, LWB low roof and LWB high roof forms with an 83 kWh LFP battery, and has been joined by an SLWB high roof variant using a 106 kWh NMC pack.MASSACHUSETTS TARGETS EVS FOR GRID PAYMENTSMassachusetts plans to add electric cars to its virtual power plant under the next phase of ConnectedSolutions, paying owners to export power at peak times and extending vehicle-to-grid from school buses and commercial fleets into private driveways. The state's 150,000-plus EVs represent a notional 11.25GWh of storage at 75kWh each, though depth-of-discharge limits, charger power and everyday driving needs reduce that considerably; eligible models at launch are the Ford F-150 Lightning, Nissan Leaf, Kia EV9, Polestar 3 and Volvo EX90, paying $275 per average kilowatt delivered during summer events, or roughly $1,375 to $2,750 a season.QUEENSLAND E-BIKE CRACKDOWN NETS 991 TICKETSQueensland police issued 991 traffic infringement notices to e-bike riders in the first month of Operation Yankee Surety, which began on 1 July, averaging 32 a day, alongside 249 impounded illegal machines and 24 people charged with drink-riding. The crackdown rests on new laws allowing roadside seizure of non-compliant devices and breath-testing, with devices capable of exceeding 25km/h (15.5mph) banned outright and motors required to be restricted to that limit.ROMANIAN POWER CRUNCH STOPS FORD AND DACIAFord and Dacia have halted production at their Romanian factories through Aug. 19 after severe electricity shortages hit the country. Ford has suspended production of the Puma Gen E in Craiova, 230 km (134 miles) west of Bucharest.TESLA MODEL 3 POWERS HANDMADE MINI JETBOATYouTuber Tyler Fever spent three years stripping a 2021 Tesla Model 3 and fitting its drivetrain into a handbuilt aluminium mini jetboat hull, machining a custom output shaft to bypass the 9:1 reduction and couple the rotor directly to the jet pump, since the motor's roughly 18,000 rpm gave around 2,000 rpm against the 6,000–8,000 rpm impellers need. He used a standard-range pack for its smaller footprint, mounting four modules of about 150 lbs (68 kg) each vertically in laser-cut enclosures, and had to replace the factory BMS and motor controller with an Orion BMS and third-party inverter after they failed to communicate, with the series covering a successful lake run and later testing in Nashville.

This week we listened to America's favorite celebration of backless underpants, Thong Song by Sisqo, released Feb.15, 2000. This guy loves thongs and we have questions. Spoiler alert this episode features very few thongs despite the song title.  Also in this prepisode music news of the weird, listener emails and we announce next week's album.  In this episode we discuss Tim's new obsession with Looksmaxxing, when nicknames go wrong, the appropriate amount of fudge per serving, the invention of the thong, why no one should be friends with Chris Brown, Tim shouting about BMs in public, destroying pool inflatables, why everyone is in Saudi Arabia these days, practical jokes with Anthony Hopkins, and so much more!  Hatepod.com | TW: @AlbumHatePod | IG: @hatePod | hatePodMail@gmail.com Episode Outline: Quick update on the goings on at the world headquarters Discuss our history with the song/band Song discussion - lyrics and music Music Video How the song did worldwide Amazon reviews Listener email (just 2) Music news of the weird Announce next week's album

US equity futures are trading higher, with the S&P up around 0.6%. Bonds are firmer, with the US 10-year yield down 2 bps at 4.7% and the Bund down 5 bps at 3.2%. The dollar is mixed, firmer against the euro, sterling, and the Aussie, but under pressure versus the yen following FX intervention. In commodities, oil is notably weaker, with WTI crude down 6.5% below $80 a barrel, while gold is trading firmer and industrial metals are mostly lower. Bitcoin is also lower. Market sentiment is benefiting from news that President Trump called off planned strikes against Iran to allow room for negotiations over Strait of Hormuz. Trump said talks would begin Monday and posted parameters of deal have been agreed to. Iran echoed by noting an agreement on Strait of Hormuz close. Companied mentioned: AstraZeneca, BMS, Shell Plc, Blackstone

Adam Haman returns, this time helping Bob critique Carl Jung's "Answer to Job."Mentioned in the Episode and Other Links of Interest:The YouTube version of this episode.Carl Jung's "Answer to Job."This episode's featured company, Jackery.RC Sproul on Job.BMS ep. 420 unpacking Darryl Cooper's religious heresies.The HamanNature substack.Help support the Bob Murphy Show.

We Like Shooting We Like Shooting - Ep 672 July 20, 2026 Presented by This episode of We Like Shooting is brought to you by: Foxtrot Mike (Code: WLSISLIFE) C&G Holsters (Code: WLSISLIFE) Midwest Industries (Code: WLSISLIFE) Blue Alpha Night Fision (Code: WLSISLIFE) Bowers Group (Code: WLS) Second Call Defense Giveaways!! GAW   Text Dear WLS or Reviews +1 743 500 2171 Public   Show Titles   GOA GOALS Aug 1-2 in Iowa. https://goals.goa.org/ Gear Chat Instagram (Savage) Da6kzNIulLc 36 likes, 17 comments – savage1r on July 17, 2026: "When you absolutely, positively, obsessively do not want to smell the smoke in your house during fire season. #airpurifier #air #fans #filter". https://www.instagram.com/reel/Da6kzNIulLc/?utm_source=ig_web_copy_link&igsh=MzRlODBiNWFlZA== Note Tacticaltoggle.com thefirearmblog.com Springfield Armory Echelon Alpha An Echelon, but More Affordable?Springfield Armory Unveils the NEW Echelon AlphaThe Springfield Armory Echelon is the pistol of choice for a lot of shooters because of its wide package of accoutrements and modern features.The only gripe that some shooters raise is that the more tricked out variations might be too expensive for their budget. Springfield Armory announced the Echelon Alpha, a 9mm striker-fired pistol built on the Central Operating Group with a serialized stainless steel chassis. It features a recontoured billet machined slide with Melonite finish, 4″ hammer-forged barrel, optics-ready Variable Interface System, and ships with one stainless steel magazine. The design emphasizes purpose-driven ergonomics with a small grip module and reduced overall dimensions compared to the standard Echelon. Availability: Unveiled July 14, 2026; three initial models (standard, low-capacity, CA-compliant) offered directly via Springfield Armory Cost: $599 (standard and low-capacity); $649 (CA-compliant) Special: Variable Interface System for direct optic mounting combined with recontoured slide, captive recoil system, and single stainless steel magazine shipment EnVeeGee 2.0 DIY Night Vision 1078126 Enveegee 2 0 Diy Night Vision Download this free 3D print file designed by horizonalt.  Please notify me if anything is missing.The EnVeeGee is a digital-only refinement of the PVS-69 created by VonScherfArms. Using the technology available, a more purpose-built version of Vaughn's “Alpha” was designed and built to use only Amazon, Ebay, and Aliexpress hardware. No custom electronics were used to keep this build as accessible as possible. Odysee MMMIIT V1:7 Presenting the MMMIIT, or better known as the Monolithic Monocular Mx9644 Image Intensifier Tube Note Best can for my ps-90? Bullet Points Guncadindex Tritschi 60 Seconds Timer for Shooting Range A self-built horizontal hourglass-style mechanical countdown timer using a stepper motor, GT2 belt, Nema17, Arduino Nano, and 3D-printed parts. It provides a large 160 cm x 90 mm visual window that transitions from white to red over exactly 60 seconds for timing K20-K23 handgun events in DSU disciplines, with startup red LED/beeper sequence, green LED indicator, optional beeper, and planned light-sensor start. Powered by 3S Li-Ion with BMS; designed in TinkerCad and printed on Prusa MK4/Sovol SV08. Availability: Best Use Case: Competition (K20-K23 handgun events in German DSU shooting sports; helps pace 18 shots in 60 seconds without digital distractions or crowd noise) Special: Quick Pro/Con: Pro – Large peripheral-vision mechanical analog display improves focus and timing accuracy; Con – Self-built (requires 3D printing, electronics assembly, partial BOM only; no pre-built unit or price listed) Thefirearmblog 1791 Industries LiteRaider MMC Receivers 1791 Industries introduces LiteRaider MMC (Metal Matrix Composite) AR-15/M4 receivers made from a composite of pure metals and ceramic nanoparticles. They achieve 33% weight reduction versus standard aluminum while matching the strength of 7075-T6 aluminum, with Mil-Spec tolerances, anodized or Cerakoted finishes in Black or FDE. A matching lightweight accessory ecosystem including handguards is also offered. Availability: Military, law enforcement duty use and civilian lightweight fighting rifles (range, competition, hunting, EDC) Cost: Stripped upper 4.8 oz, stripped lower 6.2 oz (combined ~3.2 oz / 91 g reduction vs aluminum); compatible with AR-15/M4 platforms and MMC accessory line Special: Pro: 33% lighter with equivalent strength and durability; Con: Long-term recoil/vibration performance untested (monitor zero retention and group sizes) Guncadindex GRIP DEEZ (Printable AK Grip Nuts) by Haymarket Customs Printable AKM grip nut designed for fastening a pistol grip to the receiver. Prints without supports in under 30 minutes using PA6-GF/CF at 100% infill for less than $1 in materials. Requires 1x M6 jam/lock nut and 1x M6 screw (length varies by grip). Availability: Best Use Case: AKM rifle pistol grip installation (home-printed accessory) Recoilweb Kimber Warrior 1911 Optimized for Duty Use The article details the optimization of a used Kimber Warrior .45 ACP 1911, a commercial homage to the MCSOCOM Det 1 ICQBP sidearm. Upgrades include a Wolff Gunsprings 18.5 lb variable recoil spring, Nighthawk Custom one-piece magwell with lanyard loop, Nighthawk drop-in trigger pack (3.75-4 lb pull), 10-8 Performance flat trigger shoe, and VZ Simonich Gunner grips. The result is a reliable, enhanced single-stack 5-inch 1911 for duty/LE or armed citizen carry at a total cost of approximately $1,500. Availability: Duty use (LE, armed citizen, bedside/survival carry); reliable duty holster sidearm and last-resort pistol, homage to MCSOCOM ICQBP Cost: 5-inch barrel, single-stack narrow frame, 7-round capacity; compatible with duty holsters; weight not numerically stated (stock ~2 lbs implied) Special: Pro: Reduced recoil, crisp 3.75-4 lb trigger with short reset, faster reloads, solid grip, cost-effective reliability. Con: Requires gunsmith fitting for trigger shoe and possible safety mods; not fully plug-and-play Inside Safariland Top 7 Common Sense Ar 15 Upgrades https://pew.report/c/A4ksrC Thefirearmblog Colt Optics LP5X-P LE-Only Multi-Emitter Aiming Laser The Colt Optics LP5X-P, developed in partnership with Brolis Defence, is a NATO-standardized, weapon-mounted aiming laser restricted to law enforcement and military use. It integrates four co-aligned emitters in a compact polymer housing: a 26 mW visible green pointer, IR pointer, electronically adjustable IR illuminator, and VCSEL IR flood illuminator, all zeroing to the same point with minimal bore offset. Powered by a single CR123A battery, it features an IP68 seal, integral flip-up backup iron sight, gloved-hand controls, and MIL-STD-1913/STANAG 4694 rail compatibility, indicating a trend toward multi-spectrum, all-in-one aiming devices for tactical operators. Availability: Best Use Case: Law enforcement and military operations (daylight visible green pointer, night vision IR pointer/illuminator/flood) Cost: Size/Weight/Compatibility: 185 grams with single CR123A battery; mounts to MIL-STD-1913 or STANAG 4694 Picatinny rails; operates -32°C to +71°C; IP68 sealed Special: Quick Pro/Con: Pro – Four co-aligned emitters (visible green 26mW, IR pointer, adjustable IR illuminator, VCSEL flood) in one NATO-fielded unit with minimal POI offset and backup iron sight; Con – Restricted to LE/military sales only (approx. $2800 MSRP noted in comments), high cost may not justify for civilian multi-emitter use over simpler setups Guncadindex BLAPR 47:3 https://pew.report/c/VJnOjT Pew Report Pew Report Adds Guncad Index To Make 3d Printed Firearms More Approachable https://pew.report/c/np1wkP Note Historical documentaries on Netflix, Thomas Jefferson, Abraham Lincoln, Lincoln, Washington, Theodore Roosevelt, Grant, FDR, sitting bull, Thefirearmblog STINC o”ST”-14 Groza Kit The STINC o”ST”-14 Groza Kit is a drop-in bullpup conversion for PSA Krink (AK-74U pattern) pistols that approximates the Russian OTs-14 Groza. It includes an iconic carry handle with adjustable rear sight (notch/post or peep aperture for 100 and 200 yards) and a forward grip module containing the trigger and trigger guard. The kit uses all-metal construction with black phosphate finish and simplified machining for dimensional accuracy; compatible with 300 BLK, 7.62×39, and 5.56 Krink variants (fitting may be required on other AK platforms). No weight, dimensions, or price are stated. Availability: Range/competition/practical shooting conversion of short AK pistol to bullpup configuration Cost: Drop-in kit for PSA Krink variants (300 BLK, 7.62×39, 5.56); all-metal black phosphate; carry handle with adjustable rear sight (100/200 yd); forward grip with integrated trigger; no weight or OAL stated Special: Pro: Dimensionally accurate Groza look on affordable Krink platform; Con: Potential fitting on non-Krink AKs, forward grip may expose hand to heat/blast (per article comments) Soldiersystems Hrt Tactical Gear Releases The Hrt Holster Adapter A Semi Flexible Mounting Platform That Moves With You Not Hinders You https://pew.report/c/6Um14L Outdoorhub FALCO Holsters Minimalist Leather EDC Tray (O206) FALCO Holsters expands its concealed-carry ecosystem with a handcrafted leather EDC tray designed for organized storage of wallet, keys, headphones, and pocket items on a nightstand or entryway. Made from premium full-grain Italian leather with hand-painted edges and reinforced stitching in the same Slovakian workshop as their holsters....

BMS Summer Fling Vol. 1  In this segment of BMS we celebrate summer and all things hot with delight. After months of cold and unstable weather, this is a time for the BBQ and good music with good friends. It's time to look forward to the weeks and months ahead and enjoy the summers of the past.   I invite you to take this journey with BMS and snap open a ‘cold one' and soak up the sun like you used to do, because before you know it - it's gone.  This episode features Sly and the Family Stone, Bill Withers, Raydio, the Isley Brothers, and many more.  PLAYLIST   Summertime/ DJ Jazzy Jeff & the Fresh Prince  Hot Fun in the Summertime/ Sly & The Family Stone  Make It Hot/Teena Marie  Let The Sun In/ Atlantic Starr  Lovely Day/ Bill Withers  Everybody/ Roy Ayers  Hot Stuff/ Raydio  Summer fling/ The O'Jays  Too Hot/ Kool & the Gang  Sunshine/ Alexander O'Neal  Summer Love/ Rick James  Sunshine (Album Version)/ Floetry  The Isley Brothers/ Summer Breeze  Picnic in The Park/ MFSB 

On the 69th episode of Enterprise AI Innovators, hosts Evan Reiser (CEO and co-founder, Abnormal AI) and Saam Motamedi (General Partner, Greylock Partners) are joined by Greg Meyers, Chief Digital and Technology Officer at Bristol Myers Squibb. Bristol Myers Squibb is one of the top ten pharmaceutical companies, with about 30,000 employees and roughly 45 billion dollars in annual revenue, making specialty medicines in oncology, immunology, and neurology. Greg shares how BMS puts commercially scalable AI products in front of doctors, why a science company had to start thinking like a data company, and how a small-team accelerator de-risks ambitious AI bets in a highly regulated industry.Quick Hits from Greg:On thinking like a data company: "to models, negative results matter as much as positive results."On running small experimental teams: "making them too small to fail in a public or embarrassing way was really important."On what really gates AI adoption: "psychology and sociology trump technology every time."Like what you hear? Leave us a review and subscribe to the show on Apple, Spotify, and YouTube.Enterprise AI Innovators is a show where top technology executives share specific ways AI changes how work gets done in the enterprise.Find more great insights from technology leaders and enterprise software experts at https://www.enterprisesoftware.blog/Enterprise AI Innovators is produced by Abnormal Studios.

Last week, the government ordered Apple and Google to pull at least three battery management system or BMS apps that were being used to switch off e-rickshaws mid-road. If you've been on Instagram, you've seen the videos. A prankster opens the app, taps a switch, and a passing e-rickshaw just dies.It works because the cheap lithium batteries these vehicles run on often ship from China with their Bluetooth wide open, no password at all. The flaw was documented publicly years ago and nothing happened until it went viral. The batteries are still exposed. In this episode, host Snigdha Sharma asks what really governs safety in India's informal economy.Tune in.*We want to get to know you a little better. Tell us what you think about Daybreak here.Daybreak is produced from the newsroom of The Ken, India's first subscriber-only business news platform. Subscribe for more exclusive, deeply-reported, and analytical business stories.

In May 2026, our co-host Laurent Segalen had the privilege of chairing a high-profile panel hosted by SolarPower Europe at its annual Solar Power Summit in Brussels, one of the leading gatherings for the European solar and energy storage sectors.  In this episode, we bring you highlights from the hour-long conversation, featuring two distinguished industry leaders: Fredrik Andrén Sandberg from RWE and Hanna Kunzmann from EQT. Between them, their organisations oversee more than 10 GW of battery storage projects either in operation or under development, offering a unique perspective on the realities of financing and scaling storage assets.  The discussion addressed one of the most important questions facing the energy transition today: the bankability of battery storage investments. As battery deployment accelerates across Europe and beyond, investors, developers, and policymakers are increasingly focused on understanding the risks and opportunities that will determine the sector's long-term attractiveness.  The conversation examines battery bankability through four interconnected dimensions. First, technology risk: are batteries still exposed to meaningful technological uncertainty, or have the key challenges shifted towards commercial execution? Second, commercial risk: how should investors evaluate revenue models, merchant exposure, and the growing role of hybridisation strategies? Third, regulatory risk: what policy and market-design uncertainties could affect future returns, from evolving capacity mechanisms to unexpected rule changes? Finally, digital risk: how critical are cybersecurity, battery management systems (BMS), and energy management systems (EMS) in safeguarding performance and protecting asset value over the long term?  The session attracted a packed audience in Brussels and has since been widely praised for the quality, depth, and practical insights of the discussion. Whether you are an investor, developer, policymaker, or simply interested in the future of energy storage, this episode offers a valuable window into how some of the industry's leading players assess risk and opportunity in one of the fastest-growing sectors of the energy transition.

Bob recently appeared on the "Human Reaction" podcast, where host David Rand asked him various questions concerning the economics of AI. Although frequent BMS listeners will have heard these themes before, there is new material in this discussion.Mentioned in the Episode and Other Links of Interest:The YouTube version of this episode.The Human Reaction YT channel.This episode's sponsor, the free Plan-B guide from ExPatMoney.Help support the Bob Murphy Show.

Adam Haman returns to further discuss US monetary and economic history, with an emphasis on understanding the designs of the "American System" (propounded by Hamilton and later Clay).Mentioned in the Episode and Other Links of Interest:The YouTube version of this episode.The previous BMS ep. 507 on this topic. The Phoenician League archives.This episode's sponsor, the free Plan-B guide from ExPatMoney.Bob's Understanding Money Mechanics. Bob's aggressive plan for US fiscal reform. Bob's case for Texas secession.The HamanNature substack.Help support the Bob Murphy Show.

For more information regarding this CME/CE activity and to complete the CME/CE requirements and claim credit for this activity, visit:https://www.mycme.com/courses/the-evolving-role-of-antibody-drug-conjugates-in-metastatic-triple-negative-breast-cancer-10800SummaryThis CME/CE-certified podcast will provide multidisciplinary clinicians with an evidence-based update on the evolving role of TROP2-directed antibody-drug conjugates (ADCs) in the frontline treatment of metastatic triple-negative breast cancer. A medical and an ocular oncology specialist review the latest efficacy and safety data from pivotal clinical trials evaluating ADCs, their integration into contemporary treatment algorithms, and guideline recommendations based on PD-L1 status, BRCA mutation status, and immunotherapy eligibility. Learners will explore key factors influencing treatment selection, compare the benefits and limitations of more established therapeutic options, and examine practical strategies for preventing, recognizing, and managing ADC-associated toxicities. Special emphasis will be placed on multidisciplinary approaches to the management of ocular adverse events and other clinically significant toxicities to optimize patient outcomes and support safe implementation of these therapies in clinical practice.Learning ObjectivesEvaluate the current and emerging clinical evidence surrounding the use of trophoblast cell-surface antigen 2 (TROP2)-directed antibody-drug conjugates (ADCs) in the first-line treatment of metastatic triple-negative breast cancer (TNBC)Integrate TROP2-directed ADCs into frontline treatment regimens for metastatic TNBC based on the latest clinical evidence, guidelines, and patient- and tumor-specific factorsApply multidisciplinary and patient-centric strategies for the prevention, recognition, and management of toxicities associated with the use of TROP2-directed ADCs in patients with metastatic TNBCThis activity is accredited for CME/CE CreditThe National Association for Continuing Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.The National Association for Continuing Education designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.The National Association for Continuing Education is accredited by the American Association of Nurse Practitioners as an approved provider of nurse practitioner continuing education. Provider number: 121222. This activity is approved for 0.50 contact hours (which includes 0.50 hours of pharmacology). For additional information about the accreditation of this program, please contact NACE at info@naceonline.com.Faculty and Moderator Aditya Bardia, MDProgram Director, Breast Medical Oncology, UCLAProfessor of Medicine, UCLALos Angeles, CADr. Bardia has disclosed the following financial relationships:Consultant: Alyssum, AstraZeneca/Daiichi, BMS, Eli Lilly, Genentech, Gilead, Menarini, Merck, Novartis, Pfizer, VyomeAdvisor/Advisory Board: Alyssum, AstraZeneca/Daiichi, Eli Lilly, Genentech, Gilead, Menarini, Merck, Novartis, Pfizer, VyomeContracted Research: AstraZeneca/Daiichi, Eli Lilly, Genentech, Gilead, Menarini, Merck, Novartis, PfizerStock options: Vyome (immuno-inflammatory and rare diseases)All of his consultant, advisor/advisory board, and contracted research disclosures are related to cancer.Maura Di Nicola, MDAssistant Professor of OphthalmologyBascom Palmer Eye InstituteMedical Director of Imaging and EchographyBascom Palmer Eye InstituteMiami, FLDr. Di Nicola has disclosed the following financial relationships:Consultant: AbbVie (ophthalmology), SpringWorks Therapeutics (oncology)Advisor/Advisory Board: AbbVie (ophthalmology)Research Grant: Castle Biosciences (ocular oncology)Please review additional planner disclosures here.Disclosure of Commercial SupportThis educational activity is supported by a medical education grant from AstraZeneca Pharmaceuticals and a medical education grant from Daiichi Sankyo, Inc.Please visit  http://naceonline.com to engage in more live and on demand CME/CE content.

Hour 4 of June 8, 2026 Jacob Townsend talks with Deb Williams, of Autoweek.com, about Denny Hamlin's second straight victory at Michigan, his 63rd career win, Carson Hocevar, Chase Elliott/Christopher Bell crash, Ned Jarrett passing, and more. Then, Jacob is joined by Brandon Cross, of Bristol Motor Speedway, to promote Super Grip NHRA Thunder Valley Nationals this weekend at BMS. Also, Jacob talks about Denny Hamlin's victory and Carson Hocevar's aggressiveness. See omnystudio.com/listener for privacy information.

Jacob Townsend is joined by Brandon Cross, of Bristol Motor Speedway, to promote Super Grip NHRA Thunder Valley Nationals this weekend at BMS.See omnystudio.com/listener for privacy information.

Adam Haman returns to help Bob offer praise and criticism for Jeremy Kauffman's recent speech at the Libertarian Party's national convention, as well as his appearance on the Tom Woods Show.Mentioned in the Episode and Other Links of Interest:The YouTube version of this episode.Jeremy Kauffman's appearance on the Tom Woods Show. His address to the LP national convention.Jeremy's interview on BMS ep. 368.This episode's sponsor, the free Plan-B guide from ExPatMoney.The "Universal Principles of Liberty."The HamanNature substack.Help support the Bob Murphy Show.

At the American Society of Clinical Oncology (ASCO) annual meeting in Chicago this past weekend, packed plenary sessions from Revolution Medicines and Summit Therapeutics' Chinese partner Akeso stole the show. For RevMed, analysts anticipate a potential approval in pancreatic cancer as early as this year, while Summit still has a tough road ahead showing that the survival benefit seen in Akeso's clinical trial in China will hold up in a global population.Immuneering, BMS/BioNTech, Merck, Pfizer and many more also scored oncology wins at the annual meeting, as did Moderna, with “encouraging” 5-year survival for its mRNA-based personalized melanoma vaccine. Outside of ASCO, the past week saw Pfizer strike an unusual pact with China's Innovent Biologics as it seeks to bolster its oncology pipeline. Reminiscent of another recent deal from BMS and Hengrui Pharma, it could signal a more collaborative approach to working with Chinese companies. We'll also cover the latest deals from Eli Lilly, which continues to rack up partners with its GLP-1 windfall. Finally, learn about how BrainStorm is planning another FDA bid for its experimental ALS therapy NurOwn with former regulator Peter Pitts now on the board, and check out a preview of the 2026 American Diabetes Association, or ADA, which kicks off this weekend in New Orleans.

Welcome to IDEA Collider. In this episode, host Alex Gray is joined by IDEA Pharma colleagues David Radwaner and Tom Brockbank to dissect the history, strategy, and future of immuno-oncology (IO). The trio explores how PD-1 and PD-L1 therapies revolutionized cancer treatment, acting as a brake on the immune system to offer unprecedented durability and long-term survival for patients.  They take a deep dive into the fascinating commercial and clinical race between Merck's Keytruda and BMS's Opdivo. Learn how Merck's strategic decisions—including smart statistical trial designs, targeted biomarker approaches in first-line non-small cell lung cancer, and tumor-agnostic labels like MSI-high—allowed Keytruda to secure market dominance. Finally, Alex, David, and Tom look ahead to the next ten years, discussing whether emerging players like AstraZeneca and China's Akeso / Summit will displace Keytruda, or if the future lies in combination therapies.    Episode Timestamps:  00:00:00 - Introduction: Meet David Radwaner, Tom Brockbank, and host Alex Gray.  00:01:45 - The Origins of IO: The Nobel Prize-winning discovery of PD-1 and CTLA-4 checkpoints.  00:03:55 - Why PD-1 / PD-L1 Won: The unique breadth of utility and unparalleled durability of long-term survival.  00:06:21 - Keytruda vs. Opdivo: How Merck's strategic trial design and smart statistical work outpaced BMS's early lead.  00:11:48 - The NSCLC Inflection Point: Why narrowing the patient population (PD-L1 - 50%) cemented Keytruda's foundation in first-line lung cancer.  00:14:20 - Tumor-Agnostic Success: Merck's bold move into MSI-high and broad biomarker-led strategies.  00:16:09 - Science or Luck? Analyzing Merck's aggressive and risky clinical development strategy.  00:18:00 - The Next 10 Years: Will anyone displace Keytruda? Assessing the future strategies of Merck, BMS, AstraZeneca, and Akeso/Summit    Don't forget to Like, Share, Subscribe, Rate, and Review!   Keep up with Alex Gray;  LinkedIn: https://www.linkedin.com/in/alexander-gray-934a653/    Keep up with David Radwaner;  LinkedIn: https://www.linkedin.com/in/david-radwaner-1b496343/    Keep up with Tom Brockbank;  LinkedIn: https://www.linkedin.com/in/tom-brockbank-159bb4116/      Follow IDEA Pharma On; Website: https://www.ideapharma.com/    Listen to more fantastic podcast episodes: https://ideacollider.simplecast.com/

With co-author Chris Coyne, Abby Hall has a new book serving as an introduction to the Austrian School. As she and Bob discuss, the book fills a niche in the existing options of this genre.Mentioned in the Episode and Other Links of Interest:The YouTube version of this episode.Abby Hall's new book (co-authored with Chris Coyne), Austrian Economics: An Introduction.The prior BMS interview of Abby (on Latin American military intervention).Help support the Bob Murphy Show.

Thank you for joining us for our 2nd Cabral HouseCall of the weekend!   I'm looking forward to sharing with you some of our community's questions that have come in over the past few weeks…   Emily: Hi Dr Cabral, you are just such an amazing soul! Keep doing gods great work! I'm writing in to ask about my personal situation, I am 34, I had a throat cancer back in 2019, underwent radiation and surgery. Since then I had 2 babies, and came down with autoimmune symptoms this last year 2025. Since then I dove into healing myself, finished a gut program, did "big 5" labs, just did a 3 month mold detox. I am a year out and my food sensitivities are gone, brain fog gone, gut healed. But what is remaining is rosacea still, and I just did a teeth cleaning and we are still seeing inflamed gums. I am working with a practitioner and we know I have some viruses to tackle next and boost my immune system. At this point is there anything more you would add, to help me get rid of remaining rosecea?      Ashley: Hi Dr. Cabral! I installed the hydrogen water device you recommended in my home last summer. My family loves it, however whenever I personally drink the water I get SEVERELY constipated. I have run 4 tests now over the last 6 months and every time I reintroduce the water (even at a low pH and titrating up as advised by your team) the constipation returns. Ironically the very first week I tried the water I was having 3-4 BMs a day before the constipation trend began. Do you have any ideas what could be going on? I'm an IHP-L2 and have consulted your team and the support groups, but everyone seems perplexed... hence my outreach to you directly on this one. Note I did the CBO protocol 2x last yr for recurring gut infections before uncovering I have mold toxicity & am now on this protocol.      Brett: Hi Dr. Cabral—I'm seeking guidance on refractory hypercoagulability. I've had 77 DVTs and 33 pulmonary emboli, and was diagnosed with antiphospholipid syndrome two years ago. Despite therapeutic anticoagulation with daily Arixtra (fondaparinux), I continue to develop thrombotic events. Are there evidence-informed adjunct strategies (e.g., anti-inflammatory protocols, micronutrient optimization, endothelial support, or additional labs) that may help reduce clot recurrence alongside standard care? I remain under physician management but am exploring complementary approaches to improve outcomes. Thank you.       Kay: Dear Dr. Cabral- Thank you so much for the work you are doing and all your super informative podcasts. I took the Minerals & Metals test end of 2024 which showed high mercury and aluminum so in November of 2025 I had all 4 of my mercury amalgams removed by a biological dentist who is SMART certified. After removal, I did my Heavy Metal Detox for 8 weeks. I then retested at the beginning of April and just received my test results and was dismayed to see Mercury levels exactly the same and the aluminum slightly higher, even. Several other minerals were off balance as well. My question to you is how long would it take to detox from amalgam removals and should I do another heavy metal detox? Or did I retest too early? Appreciate your help, Kay       Kay: Hi Dr Cabral, Recently I had conventional bloodwork labs done and repeated (Mar 31st, April 3rd) testing high in magnesium levels (2.4 mg/dL and 2.5 mg/dL, respectively) and experienced symptoms of palpitations at night. My functional medicine Dr told me to stop taking any supplements/nutritional beverages containing Mg (i.e. CALM Mg powder) which I did. Even more of a surprise was when I received my recent Minerals & Metals test back, done around the same time as my blood tests, showing that I had an elevated Ca/Mg ratio (7.9) indicating relative Mg deficiency and elevated Na/Mg ratio (5.3) also indicating a relative Mg deficiency. How could both of these labs be true? Could stress play a factor? I recently moved and am caring for parents, 1 who has been Dx'd w/cancer.     Thank you for tuning into this weekend's Cabral HouseCalls and be sure to check back tomorrow for our Mindset & Motivation Monday show to get your week started off right!   - - - Show Notes and Resources: StephenCabral.com/3761 - - - Get a FREE Copy of Dr. Cabral's Book: The Rain Barrel Effect - - - Join the Community & Get Your Questions Answered: CabralSupportGroup.com - - - Dr. Cabral's Most Popular At-Home Lab Tests: > Complete Minerals & Metals Test (Test for mineral imbalances & heavy metal toxicity) - - - > Complete Candida, Metabolic & Vitamins Test (Test for 75 biomarkers including yeast & bacterial gut overgrowth, as well as vitamin levels) - - - > Complete Stress, Mood & Metabolism Test (Discover your complete thyroid, adrenal, hormone, vitamin D & insulin levels) - - - > Complete Food Sensitivity Test (Find out your hidden food sensitivities) - - - > Complete Omega-3 & Inflammation Test (Discover your levels of inflammation related to your omega-6 to omega-3 levels) - - - Get Your Question Answered On An Upcoming HouseCall: StephenCabral.com/askcabral - - - Would You Take 30 Seconds To Rate & Review The Cabral Concept? The best way to help me spread our mission of true natural health is to pass on the good word, and I read and appreciate every review!  

Synopsis: At the intersection of personal mission and biotech leadership, Rahul Chaturvedi sits down with Catherine Owen Adams, CEO of Acadia Pharmaceuticals, for a deeply personal and strategically rich conversation on leadership, commercialization, and the future of neuropsychiatry. From starting as a pharmacist in the UK to pivoting from R&D into commercial leadership at Johnson & Johnson, rising through Bristol Myers Squibb, and ultimately stepping into her first biotech CEO role at Acadia, Catherine shares how storytelling became the throughline of her career—transforming science into physician trust, investor conviction, and enterprise vision. In this episode, Catherine opens up about the personal family experiences with neurodegenerative disease that made Acadia's focus on CNS and rare disease feel like her “Goldilocks opportunity.” She offers a candid look at the realities of being a first-time CEO, managing investor ecosystems, building the right C-suite, balancing billion-dollar commercial execution with high-risk R&D, and navigating the emotional stakes of developing therapies for Parkinson's disease psychosis, Alzheimer's disease psychosis, Rett syndrome, and beyond. Rahul and Catherine also explore the seismic shifts reshaping biotech—from AI-powered commercialization and patient services to policy advocacy through BIO, FDA modernization, and the strategic pressures facing CNS innovation. This episode is both a masterclass in biotech leadership and a powerful reminder that the best CEOs don't just run companies—they tell stories that move science, markets, and patients forward. Biography: Ms. Owen Adams joined Acadia as Chief Executive Officer and as a member of our Board of Directors in September 2024. Ms. Owen Adams has over 25 years of executive level experience in the pharmaceutical industry. Prior to joining Acadia, Ms. Owen Adams served as Senior Vice President and General Manager, U.S., at Bristol Myers Squibb (BMS), where she led a $20 billion commercial business, overseeing a large and diverse portfolio of promoted brands across Oncology, Cardiovascular, and Immunology. Previously, Ms. Owen Adams held the position of Senior Vice President, Head of Major Markets at BMS, where she led commercial operations leading 6,000 employees across 19 countries in Europe, Japan, and Canada during BMS's merger with Celgene. Prior to her tenure at BMS, Ms. Owen Adams spent 25 years at Johnson & Johnson (J&J), where she held leadership roles across global, U.S., and European business units, with her last position being President, Janssen Immunology U.S. Ms. Owen Adams began her career in R&D and manufacturing at AstraZeneca. Ms. Owen Adams currently serves on the board of directors of Agios Pharmaceuticals, Inc., a publicly held company, and AssistRx, a privately held company. Ms. Owen Adams was formerly on the board of directors and chair of the compensation committee for Optinose PLC, a public specialty pharmaceutical company, and was on the board of directors of Robert Wood Johnson University Hospitals, a non-profit organization. Ms. Owen Adams earned a BSc. in Pharmacy from the University of Manchester, becoming a qualified pharmacist and member of the Royal Pharmaceutical Society (MRPhS).

La batería de un coche eléctrico no es un componente estático; es un laboratorio químico en constante ebullición y, lamentablemente, tiene fecha de caducidad. En este vídeo abrimos la "caja negra" de la degradación para explicar por qué el depósito de los coches eléctricos "encoge" con el tiempo y qué puedes hacer para evitarlo. ¿Qué es realmente la degradación? A diferencia de un motor de combustión, donde el depósito siempre tiene el mismo tamaño, las baterías de iones de litio sufren dos tipos de castigo constantes: -Degradación por calendario: El simple paso del tiempo oxida los componentes internos, incluso si el coche está parado en el garaje. -Degradación por ciclo: El estrés mecánico de cargar y descargar expande y contrae los materiales, generando microfisuras en los electrodos. Según datos actualizados a 2026, la pérdida media de capacidad se sitúa en un 2,3% anual. Esto significa que, en diez años, tu coche habrá perdido casi una cuarta parte de su autonomía original. Los tres enemigos de tu autonomía Para maximizar la vida útil de las celdas, debemos vigilar tres factores críticos: -El Calor: El litio sufre fuera de los 15°C - 35°C. El calor extremo acelera la descomposición del electrolito, creando una capa de "colesterol químico" que atrapa los iones y los deja inservibles. -La Carga Ultrarrápida: El uso sistemático de cargadores de más de 100 kW duplica la velocidad de degradación en comparación con la carga doméstica. Es un estrés térmico que la química paga caro. -Estados de Carga Extremos: Mantener el coche al 100% durante días o bajar habitualmente del 5% genera inestabilidad química y riesgos de fallos de voltaje permanentes. El peligro oculto: Las Dendritas Uno de los secretos mejor guardados es la formación de dendritas. Estas estructuras ramificadas crecen cuando se abusa de la carga rápida, especialmente en frío. Si una de estas "agujas" metálicas perfora el separador interno, se produce un cortocircuito que puede derivar en un incendio químico de extrema dificultad de extinción. La trampa del software (SOH) El "State of Health" o salud de la batería es un dato calculado por el software del fabricante (BMS). Hemos detectado casos donde las actualizaciones de software "maquillan" este porcentaje, liberando capacidad de reserva oculta para que el usuario no note la degradación real. Es vital certificar la salud de la batería con herramientas externas antes de comprar un eléctrico de segunda mano. Decálogo de Supervivencia: Cómo estirar la vida de tu batería Para evitar facturas de reemplazo que pueden oscilar entre los 7.000 € en coches urbanos hasta más de 25.000 € en modelos premium, sigue estos consejos: -Regla del 20-80: Mantén el uso diario en este rango. -Carga lenta: Prioriza siempre la carga en casa (AC). -Evita el 100% estático: Si cargas al máximo, que sea justo antes de salir de viaje. -Preacondicionamiento: Calienta la batería en invierno antes de circular o cargar. -Aparca a la sombra: Evita que el suelo caliente "cocine" las celdas. -Conducción suave: Evita picos de descarga por aceleraciones bruscas. -No llegues al 0%: Podrías dejar la batería en un estado de "sueño profundo" irreversible. -Freno regenerativo: Úsalo para recuperar energía de forma suave. -Actualizaciones: Mantén el software al día para mejorar la gestión térmica. -Certificación real: Usa dispositivos OBD2 para conocer el estado real de la química. La movilidad eléctrica actual exige un usuario consciente. Mientras no lleguen las baterías de estado sólido a finales de esta década, cuidar la química es la única forma de evitar que tu coche se convierta en un gasto inasumible.

Adam Haman returns to help Bob respond to Martyr Made's recent appearance on Jacob Winograd's Biblical Anarchy podcast.Mentioned in the Episode and Other Links of Interest:The YouTube version of this conversation.Darryl's appearance on Jacob Winograd's show.A previous BMS covering Oregon's drug decriminalization.This episode's sponsor, The Swan Brothers.The HamanNature substack.Help support the Bob Murphy Show.

Agradece a este podcast tantas horas de entretenimiento y disfruta de episodios exclusivos como éste. ¡Apóyale en iVoox! En este episodio de La Ola Eléctrica nos adentramos en uno de los temas más importantes, y a la vez menos comprendidos, del coche eléctrico: las baterías. Durante décadas, el motor fue el corazón del automóvil. Pero en la era eléctrica, el centro de poder se ha desplazado bajo el suelo del vehículo. La batería decide la autonomía, el precio, la carga rápida, la vida útil, la seguridad, el peso y hasta la estrategia industrial de países enteros. Hablamos de cómo funciona una batería de coche eléctrico, qué elementos la componen, qué papel tienen el ánodo, el cátodo, el electrolito, el separador y el BMS, y por qué no todas las baterías son iguales. Analizamos las principales tecnologías actuales: LFP, NCM, NCA, LMFP, baterías de sodio y las prometedoras baterías de estado sólido. También explicamos por qué China ha tomado tanta ventaja con gigantes como CATL y BYD, por qué Europa ha reaccionado tarde, qué papel juegan materiales como el litio, el níquel, el cobalto, el grafito o el sodio, y por qué el reciclaje será clave en la próxima década. Un episodio para entender que la batería no es solo un componente más del coche eléctrico: es el nuevo motor, el nuevo campo de batalla industrial y una de las claves que decidirán qué marcas y qué países liderarán la movilidad del futuro.Escucha este episodio completo y accede a todo el contenido exclusivo de Somos Eléctricos. Descubre antes que nadie los nuevos episodios, y participa en la comunidad exclusiva de oyentes en https://go.ivoox.com/sq/627406

Podcast: PrOTect It All (LS 27 · TOP 10% what is this?)Episode: Cyber Risk in Construction: Securing AEC Projects in a Digital, AI-Driven WorldPub date: 2026-04-27Get Podcast Transcript →powered by Listen411 - fast audio-to-text and summarizationConstruction sites are no longer just physical - they're digital, connected, and increasingly vulnerable. In this episode of Protect It All, host Aaron Crow sits down with Lee Carsten to explore the rising cyber risks across the architecture, engineering, and construction (AEC) industry. As digital transformation accelerates - with AI, digital twins, and connected building systems becoming standard - construction projects are expanding their attack surface in ways many organizations don't fully understand. Aaron and Lee unpack the unique challenges facing AEC environments, from fragmented systems and evolving workflows to the growing need for integrating cybersecurity into business decisions - not just IT functions. You'll learn: Why construction and infrastructure projects are becoming prime cyber targets How digital transformation and AI are reshaping risk in AEC environments The role of building management systems (BMS) and OT in modern projects Why foundational controls and human awareness still matter most How to align cybersecurity with real-world construction workflows Practical strategies to build resilience into projects from day one Whether you're in construction, engineering, IT, or OT security, this episode delivers real-world insights to help you protect the infrastructure we rely on every day. Tune in to learn how to secure modern construction in a connected world - only on Protect It All. Key Moments:  05:39 Importance of interpersonal skills 08:08 Construction security and recent projects 11:46 Challenges in AEC industry adoption 19:30 Importance of disaster recovery 20:31 Discussing costs of business interruptions 24:06 RFP process and bid management 27:25 Complexity of building projects 32:02 FBI investigation triggers and readiness 36:55 Managing complex building assets 39:37 Choosing durable equipment and future tech 42:01 Understanding OT data for security About the guest :  Lee Carsten's journey in technology began in the era of punch cards - painstakingly sorted and fed into compilers, where a single fumble could mean hours' worth of work undone. Lee studied COBOL in college, envisioning a future as a programmer. That path nearly led to Walmart, where Lee's mother worked on the company's pioneering buyer decision support system under Randy Mott. While the family connection and an offer from Kevin Turner to join a new team were tempting, Lee ultimately decided against moving to Bentonville and working for $18,000 annually. This early exposure to large-scale business technology, combined with pivotal career choices, shaped Lee Carsten's perspective on IT and the evolving world of software development. How to connect Lee: https://www.linkedin.com/in/leecarsten/ Website: https://whitecaprisk.com/ Connect With Aaron Crow: Website: www.corvosec.com  LinkedIn: https://www.linkedin.com/in/aaronccrow Learn more about PrOTect IT All: Email: info@protectitall.co  Website: https://protectitall.co/  X: https://twitter.com/protectitall  YouTube: https://www.youtube.com/@PrOTectITAll  FaceBook:  https://facebook.com/protectitallpodcast To be a guest or suggest a guest/episode, please email us at info@protectitall.co Please leave us a review on Apple/Spotify Podcasts: Apple   - https://podcasts.apple.com/us/podcast/protect-it-all/id1727211124 Spotify - https://open.spotify.com/show/1Vvi0euj3rE8xObK0yvYi4The podcast and artwork embedded on this page are from Aaron Crow, which is the property of its owner and not affiliated with or endorsed by Listen Notes, Inc.

This week, Jimmy and Tyler catch up on two very different 4Runner projects — and somehow both of them involve things that were bent, broken, or seized in ways nobody’s seen before. Jimmy’s 4Runner “Samantha” is making progress. He spent the week fabricating temporary shock towers out of scrap steel, getting the shocks roughly mounted, and articulating the suspension to figure out how much travel he’s actually working with. The verdict: he needs to raise the shocks about a half inch, the bump stops are in the right ballpark, and the Panhard bar collision he was worried about looks like it won’t be an issue once the setup is dialed. He also talks through the surprisingly useful difference between working with metal vs. wood — and why metal scrap is genuinely hard to throw away. Tyler’s 4Runner “The Mule” went to Jason at OCD Innovations for a full teardown, and what they found was wild. The pinion bearing had seized and welded itself to the housing — which is what caused the axle lockup and the subsequent catastrophic failure. The good news: the Mile Marker hubs actually survived and held. The not-so-good news: basically everything else needed replacing — lower links (bent aluminum), upper link bracket, CV joints (Metal Cloak), steering kit (Sidetrack Off Road), DOM tubing for the track link and Panhard bar, and a driveshaft joint that exploded and saved the front diff case in the process. The one remaining unknown is the rear diff. Jason is being thorough — almost comically so — and the mule is back on four wheels, running under its own power. Registration still has to happen, which means blinkers, safety inspection, and a Switch-Pros wiring job are all still on the list. They also get into a deep conversation on lithium battery setups — starter battery vs. auxiliary battery, how alternators interact with lithium BMS shutoffs, and why Tyler is landing on a Dakota Lithium battery with a DC charger as his power management strategy. Off the trail: Jimmy went and saw *Project Hail Mary* in theaters and loved it (verdict: great home watch, doesn’t require the big screen). He ran a 10K at the Run Rockland event and surprised himself with a 9:45/mile average. And both Jimmy and Tyler took a moment to geek out over the Big Boy steam locomotive #4014 rolling through Roseville — 1.2 million pounds, 133 feet long, 7,000 horsepower, and apparently enough to stop traffic and make kids forget trains exist in favor of radio towers. SnailTrail4x4 Discord: https://discord.gg/yFyFFkQbuyCome hang out with us on the SnailTrail4x4 Discord — it’s the easiest way to connect with Tyler and Jimmy directly, chat with fellow offroad enthusiasts, and get first access to Group Buys and Treasure Hunt token drops. Group Buy for the Devos LightRanger 500We reached out to Devos, and they are in. Here’s how the discount tiers work: 10 people → 15% off (~$60/light) 20 people → 20% off (~$56/light) 30+ people → 25% off (~$52/light) These retail at $70. To get in, just send us your email and how many units you want. You can email us at jimmy@snailtrail4x4.com or tyler@snailtrail4x4.com, or DM us on Instagram. Deadline: April 30th. Want to learn more about the LightRanger 500? Click Here: https://www.devosoutdoor.com/products/lightranger-500 MORRFlate Giveaway at 900 Reviews on Apple Podcast. But our next giveaway is when we reach 800 reviews; we are giving away an OnX Elite Membership. We will also give away an OnX Elite membership when we get to 850. However, when we reach 900 Reviews, we are teaming up with MORRFlate for a $1000 MF Product Giveaway. Go over to Apple Podcasts to leave your review now and become eligible to win. Congratulations to A13XMONT, who won a set of tires from Yokohama Tire! Call us and leave us a VOICEMAIL!!! We want to hear from you even more!!! You can call and say whatever you like! Ask a question, leave feedback, correct some information about welding, say how much you hate your Jeep, and wish you had a Toyota! We will air them all, live, on the podcast! +01-916-345-4744. If you have any negative feedback, you can call our negative feedback hotline, 408-800-5169. 4Wheel Underground has all the suspension parts you need to take your off-road rig from leaf springs to a performance suspension system. We just ordered our kits for Kermit and Samantha and are looking forward to getting them. The ordering process was quite simple, and after answering the questionnaire, we ensured we got the correct and best-fitting kits for our vehicles. If you want to level up your suspension game, check out 4Wheel Underground. SnailTrail4x4 Podcast is brought to you by all of our peeps over at irate4x4! Make sure to stop by and see all of the great perks you get for supporting SnailTrail4x4! Discount Codes, Monthly Give-Always, Gift Boxes, the SnailTrail4x4 Community, and the ST4x4 Treasure Hunt! Thank you to all of those who support us! We couldn’t do it without you guys (and gals!)! SnailSquad Monthly Giveaway For the Month of April, we are giving away Gift Boxes. Its Gift Box month and two luck indiviuals will win a one of our gift boxs. These are jam packed with goodies from tools to whiskey smokers. They are always different and always random. If you want a chance to win, sign up for the Giveaway Tier on Irate4x4 Congrats to Roger Lutz on March’s Giveaway. We gave away the new Devos LightRanger500. This little light is jam-packed with features, from red, orange, and white lights to a motion sensor. It would be perfect for inside a tent, under a canopy, or just general use around the vehicle. If you want a chance to win, sign up for the Giveaway Tier on Irate4x4 Listener Discount Codes: SnailTrail4x4 –SnailTrail15 for 15% off SnailTrail4x4 MerchMORRFlate – snailtraill4x4 to get 10% off MORRFlate Multi Tire Inflation Deflation™ Kits4WheelUnderground – snailtrail 10% offIronman 4×4 – snailtrail20 to get 20% off all Ironman 4×4 branded equipment!Sidetracked Offroad – snailtrail4x4 (lowercase) to get 15% off lights and recovery gearSpartan Rope – snailtrail4x4 to get 10% off sitewideShock Surplus – SNAILTRAIL4x4 to get $25 off any order!Mob Armor – SNAILTRAIL4X4 for 15% offSummerShine Supply – ST4x4 for 10% offBackpacker’s Pantry – Affiliate LinkLaminx Protective Films – Use the Link to get 20% off all products (Affiliate Link) Show Music: Outroll Music – Meizong Kumbang Midroll Music – ComaStudio

Bob continues his commentary on John chapter 3, this time on verses 18 through 36 (finishing the chapter). The emphasis is on the humility of John the Baptist, and the fact that you need a savior.Mentioned in the Episode and Other Links of Interest:The previous episode in this series, i.e. BMS ep 487, Installment 11: Whoever Believes in Him.RC Sproul on Jesus as the light.Help support the Bob Murphy Show.

Nard engages with the BMS chatroom and basically becomes a listener, cheat fantasies and more!

This Biotech CEO Created The RedTail Platform To Fight Cancer. Guest:Eric PomaCEO of Calidi Bio CLDI Company Name:Calidi BiotherapeuticsWebsite: https://www.calidibio.com/Ticker: NYSE: CLDIEric's Bio:Eric Poma, Ph.D. has served as Chief Executive Officer and board director of Calidi since April 2025 and brings more than 30 years of experience in the biopharmaceutical industry, with a strong record of capital fundraising, big pharma collaboration agreements, and clinical program development.Prior to joining Calidi, Dr. Poma served as CEO of Molecular Templates (NASDAQ: MTEM), a clinical-stage biotech focused on the development of a novel class of therapeutic agents with unique biology in oncology. At Molecular Templates he raised over $250 million in equity financing and secured over $150 million in strategic capital through agreements with Takeda, Vertex and BMS. He previously served as Vice President, Business Development of Innovive Pharmaceuticals. Prior to that he held various senior level positions at Imclone Systems, Inc., primarily in business development. Earlier, Dr. Poma served as a Healthcare & Biotechnology Analyst with the healthcare fund Eagle Growth Investors, LLC.Dr. Poma received a Ph.D. in Microbiology and Immunology from the University of North Carolina at Chapel Hill, an M.B.A. from the Leonard N. Stern School of Business and a Bachelor of Science in Biology from the University of North Carolina at Chapel Hill.Company Bio:Calidi Biotherapeutics is a biotechnology company pioneering the development of targeted genetic medicines for cancer and other diseases through its RedTail platform. The company's lead compound, CLD-401, is a systemically delivered oncolytic virus that expresses high levels of IL-15 superagonist only in the tumor microenvironment. The company expects to file an IND to initiate clinical studies for CLD-401 by the end of 2026. The company continues to advance what the RedTail platform can achieve and will be presenting additional data throughout the year.

In this episode, we welcome Kirollos Hanna, PharmD, BCPS, BCOP, a recognized leader in oncology pharmacy practice and research. Dr. Hanna shares insights into the evolving landscape of antibody-drug conjugates (ADCs) and the unique challenges they present in managing chemotherapy-induced nausea and vomiting (CINV).  As ADC use expands, oncology teams are observing new and sometimes underrecognized patterns of nausea and vomiting, particularly with HER2-directed therapies and delayed-phase symptoms that extend beyond the traditional monitoring window. This discussion highlights how these patterns differ from conventional chemotherapy and what that means for clinical practice.  Dr. Hanna also reviews emerging pharmacokinetic data and clinical trial evidence supporting the use of NK1 receptor antagonist–based antiemetic strategies. The conversation emphasizes practical, actionable approaches for optimizing supportive care, improving patient quality of life, and ensuring proactive symptom management within the medically integrated oncology team.  Learning Objectives:  Describe emerging patterns of chemotherapy-induced nausea and vomiting (CINV) associated with antibody–drug conjugates (ADCs), with emphasis on HER2-directed ADCs and delayed-phase nausea beyond day 5  Discuss pharmacokinetic and clinical trial evidence on NK1 receptor antagonist–based antiemetic strategies when optimizing CINV prevention for patients receiving ADC therapy.  This episode offers 0.5 CE credit hours to pharmacists and pharmacy technicians. Claim CE credit here. Guest: Kirollos Hanna, PharmD, BCPS, BCOP, Director of Pharmacy, Minnesota Oncology, Assistant Professor of Pharmacy, Mayo Clinic College of Medicine, Associate Editor, Journal of the Advanced Practitioner in Oncology (JADPRO)  Disclosures: Speaker: BeOne, BMS, Exelixis, Pfizer Consulting Fees: BeOne, BMS, Exelixis, Pfizer, Astrazeneca

Bob was recently on the "What Is Money?" podcast to probe the philosophical underpinnings of Austrian economics.Mentioned in the Episode and Other Links of Interest:The YouTube version of this interview.HHH's Economic Science and the Austrian Method (ESAM).BMS ep 7 explaining Godel's theorem.Bob's earlier appearance on "What Is Money?" (recorded on-site at the inaugural ARC conference).Help support the Bob Murphy Show.

Michael Fraser is a business consultant on leading LLMs, with an extensive knowledge of praxeology. He joins Bob to discuss the Pentagon's decision to sever ties with Anthropic and even designate them a supply chain risk.Mentioned in the Episode and Other Links of Interest:The YouTube version of this interview.Anthropic CEO's statement in response to Hegseth decision.Academic paper putting leading LLMs into a wargame.Good examples of "jailbreaking" safeguards on LLMs.The BMS interview of Steve Landsburg discussing Grothendiek.Michael Fraser's interview on the InFi podcast, discussing LLMs as a cauldron, not a crystal ball.Help support the Bob Murphy Show.

Adam Haman returns, this time to discuss a recent paper summarizing the performance of leading LLMs in wargames.Mentioned in the Episode and Other Links of Interest:The YouTube version of this conversation.The NewScientist article reporting (inaccurately) on this research paper.BMS ep 467 on the weaknesses of modern game theory.This episode's sponsors, the Scott Horton Academy and The Swan Brothers.The HamanNature substack.Help support the Bob Murphy Show.

Bob continues his commentary on John chapter 3, this time on verses 13 through 17. This includes the famous verse John 3:16, which lays out the recipe for eternal life through belief in Jesus.Mentioned in the Episode and Other Links of Interest:The previous episode in this series, i.e. BMS ep 475, Installment 10: Being Born Again.John Piper on Moses lifting up the serpent.John Piper answers: Does God love the non-elect? Help support the Bob Murphy Show.